Brussels (ots/PRNewswire) - First study to investigate the
protective effect of a lipid-lowering agent on diabetic eye disease
to be published on-line in Lancet, Tuesday, 6th November 2007
Diabetic eye disease (called diabetic retinopathy) is the leading
cause of vision loss in adults - affecting about 25 million people
worldwide. It occurs when diabetes affects the blood vessels at the
back of the eye damaging the retina and restricting blood flow. This
destructive process occurs in about 74 per cent of people who have
diabetes for 10 years or more.
Currently, the only widely used treatment for this condition is
laser therapy. However, laser treatment often reduces peripheral
vision as well as causing other side effects. Nor does it restore
Important new results to be published in Lancet.
Now researchers in Australia, New Zealand and Finland have
investigated the effects of a widely available lipid-lowering agent,
fenofibrate, on the use of laser therapy in more than 9000 men and
women with diabetes.
The Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) Trial is the largest study of a lipid-lowering agent ever
conducted in adult diabetics.
The results of an analysis of the effects of fenofibrate on
diabetic retinopathy and a sub-study of its effects on the
progression of diabetic retinopathy in more than 1000 patients will
be published on-line in the Lancet. Here is how you can get the news
as it breaks:
For a copy of the press release and details of Webcast, go and
register on: http://www.fieldstudy.info/reg2 on November 7th
ots Originaltext: Solvay Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.ch
For more information contact: Solvay pharmaceuticals contact, Neil E.
Hirsch Manager, U.S. Corporate Communications, Solvay
Pharmaceuticals, Inc., Mobile: +1-678-557-2952, E-mail:
firstname.lastname@example.org; Solvay pharmaceuticals B.V., Pharmacom, Puck
Bossert, +31-29-44-77-469, E-mail: email@example.com